Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | CDK12 R858W |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| CDK12 R858W | prostate cancer | decreased response | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, expression of CDK12 R858W in CDK12 knockout prostate cancer cell lines demonstrated reduced sensitivity to Rubraca (rucaparib) compared cells with the CDK12 knockout alone in culture (PMID: 39321214). | 39321214 |